BioNTech SE shareholders approved all resolutions at the 2026 virtual Annual General Meeting, including Supervisory Board expansion, new member elections, and authorized capital renewal, with 92% of share capital represented.
Key takeaways
All 11 agenda items approved by majority vote at the AGM held on May 15, 2026.
Supervisory Board expanded from 6 to 8 members; new elections: Prof. Dr. Iris Loew-Friedrich and Dr. Susanne Schaffert.
Mandates extended for Helmut Jeggle (elected Chairman), Prof. Dr. Anja Morawietz, and Prof. Dr. Rudolf Staudigl.
92% of share capital represented; Compensation Report approved despite 3.40% no votes.
Authorized Capital 2025 cancelled and new Authorized Capital 2026 created with subscription rights exclusion possible.
Virtual AGM authorization renewed and domination agreement with BioNTech Discovery GmbH approved.